Breaking News

OsoBio Appoints Manufacturing Director

March 31, 2014

Buck brings 20 years of project management experience

Catherine R. Buck has been appointed director of manufacturing at OsoBio. Ms. Buck is responsible for ensuring operations comply with cGMP as they apply to the manufacture of injectable sterile liquid, suspension and lyophilized pharmaceutical products. Additionally, she will ensure compliance with appropriate FDA regulations, and direct manufacturing activities.
Ms. Buck has more than 20 years of leadership and project management experience within the pharmaceutical, medical device and construction industries, and has managed multiple commercial and clinical pharmaceutical manufacturing plants. Her experience includes the start up, process, equipment and facility validation of a new Amgen manufacturing plant that produced Epogen, as well as obtaining FDA approval of automated equipment and software, and preparing for inspection. Ms. Buck also has managed manufacturing facility operations for Johnson & Johnson and Siemens.
“The same continuous improvement expectations that bear on just about every aspect of industrial productivity exist within pharmaceutical manufacturing as well,” said Milton Boyer, president of OsoBio. “We are fortunate to add someone with Catherine’s breadth of experience to lead a manufacturing team that keeps OsoBio competitive without sacrificing our commitment to quality and cGMP compliance.”

Related Compliance:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus